Foundayo significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss – Eli Lilly
Eli Lilly and Company announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo (orforglipron) in adults with moderate-to-severe obstructive sleep apnea (OSA)… read more.
